Background Mycoplasma pneumonia （M.pneumoniae） is one of the key pathogens of community-acquired pneumonia.A global pandemic of M.pneumoniae has occurred since 2010.The aim of this study was to survey the prevalence...Background Mycoplasma pneumonia （M.pneumoniae） is one of the key pathogens of community-acquired pneumonia.A global pandemic of M.pneumoniae has occurred since 2010.The aim of this study was to survey the prevalence of M.pneumoniae in children in Beijing from 2007-2012.Methods A total of 3 073 clinical specimens were obtained from pediatric patients with respiratory tract infections from January 2007 to December 2012,and examined by nested polymerase chain reaction.PCR products were visualized by 2％ agarose gel electrophoresis,positive products sequenced,and compared with reference sequences in GenBank.Macrolide resistance-associated mutations were also detected for some positive samples.Results Of the 3 073 specimens,588 （19.13％） were positive for M.pneumoniae,12.4％ of which were accompanied by viral infections.Positive rates for M.pneumoniae were highest in 2007 and 2012,showing a significant difference when compared with other years.Infections tended to occur in autumn and winter and positive rates were significantly higher for children aged 3-16.The rate of macrolide resistance-associated mutations was 90.7％,and the predominant mutation was an A→G transition （89.92％） at position 2063 in domain V of the 23S rRNA gene.Conclusions M.pneumoniae outbreaks occurred in 2007 and 2012 in pediatric patients in Beijing,which is consistent with the global prevalence of M.pneumoniae.M.pneumoniae can cause multi-system infections in children,and may be accompanied with viral infections.We determined that school-age children are more susceptible to this disease,particularly in autumn and winter.Gene mutations associated with macrolide resistance were very common in M.pneumoniae-positive specimens during this period in Beijing.展开更多
目的:观察小青龙汤加减治疗小儿支原体肺炎的临床疗效。方法:将92例小儿支原体肺炎患者按照随机数字表法分为对照组和研究组,每组46例。对照组给予常规治疗,肺炎急性期使用布地奈德雾化液雾化治疗,肺炎症状缓解期使用孟鲁司特钠咀嚼片...目的:观察小青龙汤加减治疗小儿支原体肺炎的临床疗效。方法:将92例小儿支原体肺炎患者按照随机数字表法分为对照组和研究组,每组46例。对照组给予常规治疗,肺炎急性期使用布地奈德雾化液雾化治疗,肺炎症状缓解期使用孟鲁司特钠咀嚼片口服治疗。研究组在对照组治疗的基础上给予小青龙汤加减治疗。观察两组患者临床疗效、肺功能[用力肺活量(forced vital capacity,FVC)、最大呼气流速(peak expiratory flow,PEF)以及第1秒用力呼气容积(forced expiratory volume in the first second,FEV1)]、气道高反应性、复发情况,并检测血清白细胞介素(interleukin,IL)-4、IL-5与外周血嗜酸性粒细胞(eosinophil,EOS)水平。结果:研究组有效率91.30%,对照组有效率为76.09%,研究组有效率高于对照组,差异有统计学意义(P<0.05)。研究组治疗后FVC、PEF、FEV1水平高于对照组,差异有统计学意义(P<0.05)。研究组治疗后最小诱发累积量、促使气道阻力增加至基础值的135%所需要的组胺累积剂量高于对照组,差异有统计学意义(P<0.05)。研究组治疗后血清IL-4、IL-5与外周血EOS低于对照组,差异有统计学意义(P<0.05)。研究组复发率为19.05%(8/42),对照组复发率为42.86%(15/35),研究组复发率低于对照组,差异有统计学意义(P<0.05)。结论:小青龙汤加减治疗治疗小儿支原体肺炎,能改善患者肺功能,减轻患儿气道高反应性,调节血清IL-4、IL-5水平以及外周血EOS水平,降低复发率。展开更多
基金This work was supported by the grants from the Beijing Natural Science Foundation （No.7112019） and the Beijing City Talent Training Project Fund （No.20071A0303200118）.
文摘Background Mycoplasma pneumonia （M.pneumoniae） is one of the key pathogens of community-acquired pneumonia.A global pandemic of M.pneumoniae has occurred since 2010.The aim of this study was to survey the prevalence of M.pneumoniae in children in Beijing from 2007-2012.Methods A total of 3 073 clinical specimens were obtained from pediatric patients with respiratory tract infections from January 2007 to December 2012,and examined by nested polymerase chain reaction.PCR products were visualized by 2％ agarose gel electrophoresis,positive products sequenced,and compared with reference sequences in GenBank.Macrolide resistance-associated mutations were also detected for some positive samples.Results Of the 3 073 specimens,588 （19.13％） were positive for M.pneumoniae,12.4％ of which were accompanied by viral infections.Positive rates for M.pneumoniae were highest in 2007 and 2012,showing a significant difference when compared with other years.Infections tended to occur in autumn and winter and positive rates were significantly higher for children aged 3-16.The rate of macrolide resistance-associated mutations was 90.7％,and the predominant mutation was an A→G transition （89.92％） at position 2063 in domain V of the 23S rRNA gene.Conclusions M.pneumoniae outbreaks occurred in 2007 and 2012 in pediatric patients in Beijing,which is consistent with the global prevalence of M.pneumoniae.M.pneumoniae can cause multi-system infections in children,and may be accompanied with viral infections.We determined that school-age children are more susceptible to this disease,particularly in autumn and winter.Gene mutations associated with macrolide resistance were very common in M.pneumoniae-positive specimens during this period in Beijing.
文摘目的:观察小青龙汤加减治疗小儿支原体肺炎的临床疗效。方法:将92例小儿支原体肺炎患者按照随机数字表法分为对照组和研究组,每组46例。对照组给予常规治疗,肺炎急性期使用布地奈德雾化液雾化治疗,肺炎症状缓解期使用孟鲁司特钠咀嚼片口服治疗。研究组在对照组治疗的基础上给予小青龙汤加减治疗。观察两组患者临床疗效、肺功能[用力肺活量(forced vital capacity,FVC)、最大呼气流速(peak expiratory flow,PEF)以及第1秒用力呼气容积(forced expiratory volume in the first second,FEV1)]、气道高反应性、复发情况,并检测血清白细胞介素(interleukin,IL)-4、IL-5与外周血嗜酸性粒细胞(eosinophil,EOS)水平。结果:研究组有效率91.30%,对照组有效率为76.09%,研究组有效率高于对照组,差异有统计学意义(P<0.05)。研究组治疗后FVC、PEF、FEV1水平高于对照组,差异有统计学意义(P<0.05)。研究组治疗后最小诱发累积量、促使气道阻力增加至基础值的135%所需要的组胺累积剂量高于对照组,差异有统计学意义(P<0.05)。研究组治疗后血清IL-4、IL-5与外周血EOS低于对照组,差异有统计学意义(P<0.05)。研究组复发率为19.05%(8/42),对照组复发率为42.86%(15/35),研究组复发率低于对照组,差异有统计学意义(P<0.05)。结论:小青龙汤加减治疗治疗小儿支原体肺炎,能改善患者肺功能,减轻患儿气道高反应性,调节血清IL-4、IL-5水平以及外周血EOS水平,降低复发率。
